Infliximab as an Effective Second-Line Treatment for IVIG-Resistant Kawasaki Disease Accompanied by Severe Dyslipidemia
- DOI
- 10.1007/s00246-026-04323-y
- Published
- 2026-06-04
- Container
- Pediatric Cardiology
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1007/s00246-026-04323-y,
title = {Infliximab as an Effective Second-Line Treatment for IVIG-Resistant Kawasaki Disease Accompanied by Severe Dyslipidemia},
author = {Yuto Sunaga and Yohei Hasebe and Masashi Yoshizawa and Yosuke Kono and Keiichi Koizumi and Nobuyuki Katsumata and Takako Toda and Minako Hoshiai and Koji Kobayashi and Sho Hokibara and Hiroko Oshiro and Emi Sawanobori and Tomoaki Sano and Masanori Ohta and Makoto Tsuruta and Makoto Nakamura and Kazumasa Sato and Hiroki Sato and Takeshi Inukai},
year = {2026},
journal = {Pediatric Cardiology},
doi = {10.1007/s00246-026-04323-y},
url = {https://doi.org/10.1007/s00246-026-04323-y}
}RIS
TY - JOUR TI - Infliximab as an Effective Second-Line Treatment for IVIG-Resistant Kawasaki Disease Accompanied by Severe Dyslipidemia AU - Yuto Sunaga AU - Yohei Hasebe AU - Masashi Yoshizawa AU - Yosuke Kono AU - Keiichi Koizumi AU - Nobuyuki Katsumata AU - Takako Toda AU - Minako Hoshiai AU - Koji Kobayashi AU - Sho Hokibara AU - Hiroko Oshiro AU - Emi Sawanobori AU - Tomoaki Sano AU - Masanori Ohta AU - Makoto Tsuruta AU - Makoto Nakamura AU - Kazumasa Sato AU - Hiroki Sato AU - Takeshi Inukai PY - 2026 JO - Pediatric Cardiology DO - 10.1007/s00246-026-04323-y UR - https://doi.org/10.1007/s00246-026-04323-y ER -
APA
Sunaga, Y., Hasebe, Y., Yoshizawa, M., Kono, Y., Koizumi, K., Katsumata, N., Toda, T., Hoshiai, M., Kobayashi, K., Hokibara, S., Oshiro, H., Sawanobori, E., Sano, T., Ohta, M., Tsuruta, M., Nakamura, M., Sato, K., Sato, H., & Inukai, T. (2026). Infliximab as an Effective Second-Line Treatment for IVIG-Resistant Kawasaki Disease Accompanied by Severe Dyslipidemia. Pediatric Cardiology. https://doi.org/10.1007/s00246-026-04323-y
Source records
- crossref · retrieved 2026-09-26T18:49:41.288Z